Sandhya Panch, MD
Hematology · Seattle, WANPI 1003043415
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,358 of the $139,586 with a category attached, or 61.9%. Sobi, Inc accounts for 60.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $60,520 and has fallen 94.4% since, to $3,393 in 2025. Among hematology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $1235.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$85K
- Sanofi$37K
- Janssen Scientific Affairs, LLC$3K
- Janssen Global Services, LLC$3K
- Argenx US, Inc.$3K
- Recordati_rare_diseases_inc.$2K
- plus $5K from 8 others
Across 28 payments — averaging $13,999 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$246K
- Sanofi US Services Inc.$87K
- Sobi, Inc$46K
- Rigel Pharmaceuticals, Inc.$13K
What the payments were for
- Consulting fees$38,99528%
- Speaking & faculty fees$86,35862%
- Travel & lodging$10,8558%
- Food & beverage$3,1292%
- Education$2490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 50 | $84,826 |
| Sanofi | 32 | $37,495 |
| Janssen Scientific Affairs, LLC | 2 | $3,477 |
| Janssen Global Services, LLC | 1 | $3,375 |
| Argenx US, Inc. | 2 | $2,847 |
| Recordati_rare_diseases_inc. | 16 | $2,141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,006 |
| Amgen | 2 | $870 |
| Biomarin Pharmaceutical Inc. | 2 | $802 |
| Incyte Corporation | 1 | $685 |
| Novartis | 1 | $468 |
| Fresenius Kabi USA, LLC | 1 | $442 |
| Pharming Healthcare, Inc. | 1 | $124 |
| Johnson & Johnson | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,586 in reported general payments places this provider in the 95th percentile of 43 hematology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Seattle
- Barbara KonkleSeattle$250K
- Terry GernsheimerSeattle$148K
- Roland WalterSeattle$92K
- Cecilia YeungSeattle$42K
- Kleber Yotsumoto FertrinSeattle$29K
- Jordan GauthierSeattle$17K
- David NgSeattle$9K
- Jose LopezSeattle$8K
- Geoffrey HillSeattle$8K
- Arthur ThompsonSeattle$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.